Vyant Bio, Inc.
VYNT · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.01 | -0.21 | 0.02 |
| FCF Yield | -346.85% | -57.39% | -49.11% | -93.68% |
| EV / EBITDA | 0.25 | -0.71 | -3.78 | -1.40 |
| Quality | ||||
| ROIC | -188.69% | -119.79% | -325.99% | -27.42% |
| Gross Margin | -51.35% | -60.89% | -26.99% | 49.34% |
| Cash Conversion Ratio | 0.60 | 0.42 | 0.67 | 1.29 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.42% | -46.04% | -68.40% | -36.93% |
| Free Cash Flow Growth | 18.43% | -198.50% | 32.41% | 34.34% |
| Safety | ||||
| Net Debt / EBITDA | 0.52 | 1.24 | -1.41 | 0.44 |
| Interest Coverage | -171.10 | 0.00 | -14.25 | -1.89 |
| Efficiency | ||||
| Inventory Turnover | 19.02 | 3.89 | 2.65 | 0.00 |
| Cash Conversion Cycle | -40.97 | 85.62 | -129.63 | 34.78 |